Strides Pharma Science receives USFDA warning letter for its Puducherry facility
Puducherry site currently produces 6 ANDAs which will not get impacted by the current development. However, the 10 ANDAs pending approval from the site will get deferred till the site is reclassified.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content